Skip to content

US · STOK · BIOTECHNOLOGY

Stoke Therapeutics, Inc. (STOK) intrinsic value and stock valuation

$26.81as of 2026-11-21 · Mkt cap 1.99B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Stoke Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values STOK with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from STOK’s statements →

Stoke Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Bedford, MA 01730 stoketherapeutics.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$184.4M
20172025
Net income
-$-6.88M
20172025
Free cash flow
$44.9M
20172025
Total equity
$352.5M+4.3% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$184.4M$36.6M$8.78M$12.4M$0.00
Operating income-$-20.59M-$-101.37M-$-114.77M-$-104.36M-$-86.06M
Net income-$-6.88M-$-88.98M-$-104.7M-$-101.07M-$-85.81M
EPSd-$-116.18K-$-1.65M-$-2.38M-$-2.6M-$-2.34M
Operating cash flow$45.6M-$-86.85M-$-81.07M-$-31.87M-$-66.91M
Capital expenditure-$-670K-$-200K-$-1.62M-$-3.96M-$-1.2M
Free cash flow$44.9M-$-87.05M-$-82.68M-$-35.83M-$-68.11M
Total assets$418.4M$271.6M$228.3M$256.1M$238.9M
Total debt$3.01M$4.77M$2.06M$2.36M$5.04M
Net debt-$-81.21M-$-123.21M-$-189.38M-$-111.2M-$-139.86M
Total equity$352.5M$229M$159.6M$184.9M$217.8M
Cash and short-term investments$284.7M$216.9M$201.4M$229.6M$219.8M
Income statement
20252024202320222021
Revenue$184.4M$36.6M$8.78M$12.4M$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$184.4M$36.6M$8.78M$12.4M$0.00
Research and development expenses$137.9M$89.1M$82.2M$77.8M$54.2M
Selling, general and administrative expenses$67.1M$48.8M$41.3M$38.9M$31.9M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$205M$137.9M$123.6M$116.8M$86.1M
Cost and expenses$205M$137.9M$123.6M$116.8M$86.1M
Interest income$13.8M$12.6M$9.91M$3.12M$120K
Interest expense$10K$0.00$0.00$0.00$0.00
Depreciation and amortization$1.77M$2.18M$2.47M$1.55M$970K
Ebitda-$-5.12M-$-86.8M-$-102.23M-$-99.52M-$-84.83M
Operating income-$-20.59M-$-101.37M-$-114.77M-$-104.36M-$-86.06M
Total other income/expenses, net$13.7M$12.4M$10.1M$3.29M$260K
Income before tax-$-6.88M-$-88.98M-$-104.7M-$-101.07M-$-85.81M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-6.88M-$-88.98M-$-104.7M-$-101.07M-$-85.81M
Weighted average shares outstanding$59.2M$54M$44M$38.9M$36.7M
Weighted average diluted shares outstanding$59.2M$54M$44M$38.9M$36.7M
Balance sheet
20252024202320222021
Cash and short-term investments$284.7M$216.9M$201.4M$229.6M$219.8M
Net receivables$7.91M$700K$60K$590K$130K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$305.7M$232.8M$215.3M$244.1M$229.2M
Property, plant and equipment, net$6.25M$8.25M$12.4M$11.4M$9.08M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$29.8M$0.00$0.00$0.00
Total non-current assets$112.7M$38.8M$13M$12M$9.65M
Total assets$418.4M$271.6M$228.3M$256.1M$238.9M
Accounts payable$4.94M$2.5M$1.7M$770K$2.38M
Short-term debt$3.01M$2.32M$2.06M$2.36M$1.51M
Deferred revenue$11.9M$19M$15.3M$14.9M$0.00
Total current liabilities$57.9M$40.1M$30.8M$31.4M$17.1M
Long-term debt$0.00$2.45M$0.00$0.00$3.53M
Deferred revenue, non-current$6.96M$0.00$33.1M$36.9M$0.00
Total non-current liabilities$8.1M$2.48M$38M$39.8M$3.95M
Capital lease obligations$3.01M$4.77M$2.06M$2.36M$5.04M
Total liabilities$66M$42.5M$68.8M$71.2M$21.1M
Common stock$10K$10K$10K$0.00$0.00
Retained earnings-$-497.71M-$-490.83M-$-401.85M-$-297.15M-$-196.08M
Accumulated other comprehensive income (loss)$540K-$-150K-$-20K-$-1.18M-$-170K
Total equity$352.5M$229M$159.6M$184.9M$217.8M
Total investments$200.5M$118.7M$9.95M$116M$74.9M
Total debt$3.01M$4.77M$2.06M$2.36M$5.04M
Net debt-$-81.21M-$-123.21M-$-189.38M-$-111.2M-$-139.86M
Cash flow statement
20252024202320222021
Net income-$-6.88M-$-88.98M-$-104.7M-$-101.07M-$-85.81M
Depreciation and amortization$1.77M$2.18M$2.47M$1.55M$970K
Stock-based compensation$32.2M$27.5M$25.3M$22.9M$16.5M
Change in working capital$16.4M-$-28.14M-$-6.03M$43M$50K
Accounts receivable-$-4.27M$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$21.3M$3.09M-$-3.21M$120K$2.9M
Net cash provided by operating activities$45.6M-$-86.85M-$-81.07M-$-31.87M-$-66.91M
Investments in property, plant and equipment-$-670K-$-200K-$-1.62M-$-3.96M-$-1.2M
Acquisitions, net$0.00$0.00$0.00$45.3M$75.2M
Net cash used for investing activities-$-186.81M-$-107.47M$106M-$-45.88M-$-76.43M
Common stock issued$97.4M$128.8M$52.1M$45.3M$1.29M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$97.4M$131.1M$53M$46.4M$1.28M
Net change in cash-$-43.84M-$-63.23M$77.9M-$-31.34M-$-142.05M
Cash at end of period$84.9M$128.8M$192M$114.1M$145.5M
Operating cash flow$45.6M-$-86.85M-$-81.07M-$-31.87M-$-66.91M
Capital expenditure-$-670K-$-200K-$-1.62M-$-3.96M-$-1.2M
Free cash flow$44.9M-$-87.05M-$-82.68M-$-35.83M-$-68.11M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Stoke Therapeutics, Inc.

        Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.

        CEO
        Ian F. Smith
        Employees
        170
        Beta
        1.18

        Explore

        Frequently asked questions

        What is the intrinsic value of Stoke Therapeutics, Inc. (STOK)?

        Stoke Therapeutics, Inc. (STOK) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is STOK undervalued?

        STOK trades at a price of $26.81 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.